Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status (Q37244802)
scientific article published on 03 September 2013
Language:
(P31) (Q13442814)
(P50) (Q60394812)
(Q66370731)
(Q60320900)
(Q89744818)
(Q89447888)
(Q114428090)
(Q114428091)
(P304) 3681-3687
(P407) (Q1860)
(P433) 29
(P478) 31
(P577) Tuesday, September 3, 2013
(P921) (Q181600)
(Q29496)
(Q264118)
(P1433) (Q400292)
(P1476) "Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status" (language: en)
(P2093) Darejan Ghirdaladze
Mamia Zodelava
Robert C Armstrong
Joyce James
(P2860) (Q27851767)
(Q27851726)
(Q35127958)
(Q35048217)
(Q34193514)
(Q34063343)
(Q37724957)
(Q37704459)
(Q37373040)
(Q29547841)
(Q36669091)
(Q27824808)
(Q34784925)
(Q34524219)
(Q34517403)
(Q27824769)
(Q39981715)
(Q40252880)
(Q40543180)
(Q40490028)
(Q40736227)
(Q42192063)
(Q43244803)
(Q46858924)
(Q45042550)
(Q44679244)
(Q44189526)
(Q58290358)
(Q67900555)
other details
description scientific article published on 03 September 2013

External Links